US Stocks

uniQure N.V.

UniQure N.V. is a company that develops treatments for patients with genetic and other devastating diseases, focusing on gene therapy. Its lead program, Etranacogene dezaparvovec, is being tested in Phase III HOPE-B pivotal trial for hemophilia B. UniQure is also developing other innovative gene therapies for various diseases such as Huntington's disease, Parkinson's disease and Alzheimer's.